Approved for marketing Expanded access trials in Mexico

Showing 1 to 8 of 8. Each trial links to its page on Pharma Observatory.

• Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase NCT00905593·Expanded access·Approved for marketing·Novartis Pharmaceuticals·Started 2008
• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer NCT00338247·Expanded access·Approved for marketing·Novartis·Started 2006
• Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma NCT00130897·Expanded access·Approved for marketing·Pfizer·Started 2005
• A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 NCT00094029·Expanded access·Approved for marketing·Pfizer·Started 2004
• TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. NCT00245739·Expanded access·Approved for marketing·Tibotec Pharmaceuticals, Ireland
• The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs NCT00354627·Expanded access·Approved for marketing·Tibotec Pharmaceuticals, Ireland
• Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment NCT00683306·Expanded access·Approved for marketing·AstraZeneca
• Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer NCT01217697·Expanded access·Approved for marketing·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.